Nipah Virus Vaccine
Nipah virus infection
Pre-clinicalActive
Key Facts
About Phylex BioSciences
Phylex BioSciences is a private, pre-clinical stage biotech leveraging advanced AI and deep learning to design next-generation mRNA nanoparticle vaccines. Its core technology platform aims to overcome limitations of current vaccines, such as immune imprinting and short-lived immunity, by encoding for highly immunogenic nanoparticles. The company's pipeline targets high-fatality and emerging viruses like Nipah, SARS-CoV-2, Chikungunya, West Nile, and human metapneumovirus, positioning it in the growing field of proactive pandemic preparedness.
View full company profileTherapeutic Areas
Other Nipah virus infection Drugs
| Drug | Company | Phase |
|---|---|---|
| cVLP Nipah Virus Vaccine | AdaptVac | Pre-clinical |
| NIPAH Program | Fabentech | Proof of Concept |